3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
27
Colorectal Neoplasms
17
Esophageal Squamous Cell Carcinoma
14
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
13
Esophageal Neoplasms
12
Cholangiocarcinoma
10
Lung Neoplasms
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Small Cell Lung Carcinoma
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Nasopharyngeal Carcinoma
6
Melanoma
5
Colonic Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Locally Advanced Rectal Cancer
4
Hodgkin Disease
4
Neoplasms
3
NSCLC
3
Lymphoma, Extranodal NK-T-Cell
3
Glioblastoma
3
Carcinoma, Transitional Cell
3
Biliary Tract Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Interventions
lenvatinib
3
Gemcitabine
3
tislelizumab
2
pembrolizumab
2
Cisplatin
2
toripalimab
1
titanium silicide
1
theasinensin A
1
surufatinib
1
sitravatinib
1
sintilimab
1
durvalumab
1
S 1 (combination)
1
Nivolumab
1
Folfox protocol
1
Fluorouracil
1
Cryosurgery
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Biliary Tract Cancer
×
tislelizumab
×
Clear all
NCT04727996
2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2
Unknown
43 enrolled
NCT05823987
2023-06-27
OPTIONS-05
Fudan University
Phase 2
Unknown
25 enrolled